04.02.2016 • News

Lonza Expands Drug Product Services

Swiss fine and specialty chemical producer Lonza is building up its capabilities for drug development and manufacturing services to meet customers’ clinical outsourcing needs.

The focus will be on parenteral dosage forms, including products for injection and infusion for intravenous, subcutaneous, intraocular and other administering routes. Options will be included for monoclonal antibodies, other biologics, drug conjugates, peptides and small molecules.

The drug product services will be offered in the fourth quarter of this year from laboratories in Basel, Switzerland, and will initially center on formulation and analytical development, and quality control. Manufacturing capabilities for preclinical and clinical use will be available in late 2016.

Specialized services will also be available including: particulate identification, characterization and quantification; excipient and surfactant characterization; assessment of extractables and leachables; and testing of container closure integrity.

Marc Funk, Lonza’s chief operating officer, called the portfolio expansion an important step in becoming a one-stop-shop for all clinical outsourcing requirements.

Hanns-Christian Mahler will head the drug product business. Mahler led the departments of pharmaceutical development & supplies and formulation R&D biologics at Swiss drugmaker Roche for 10 years.

Free Virtual Event

Batteries and Hydrogen: Competitors or Partners?
CHEManager Spotlight

Batteries and Hydrogen: Competitors or Partners?

17 September 2026 | Reserve your spot to learn where solid-state batteries and green hydrogen are headed—and how leading teams are turning them into scalable energy storage solutions.

Article

The State of the US Specialty Chemicals Industry
Reshaping Specialty Chemicals Manufacturing

The State of the US Specialty Chemicals Industry

SOCMA's Jenn Klein examines how specialty chemical manufacturers — the invisible backbone behind pharmaceuticals, electronics, agriculture, and energy — are navigating supply chain shifts, policy uncertainty, and constant change while remaining resilient, disciplined, and focused on execution.

most read

Photo

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.